Every year, thousands of children are diagnosed with cancer in the United States. Sherrie and Michael Wells started the Hugs for Brady Foundation to help end pediatric cancer for good.
The Hugs for Brady Foundation is a 501 (c) (3) non-profit corporation. All donations are 100% tax deductible. The Hugs for Brady Foundation has over 500 volunteers and only one part-time administrative assistant staff member.
96% of every dollar raised by the Hugs for Brady Foundation goes directly toward…
· Funding advanced Cancer Research at centers such as The Rutgers Cancer Institute of New Jersey
· Special projects such as funding the region’s first sedation-free MRI project at New York Presbyterian Morgan Stanley Children’s Hospital
· Helping families defray the costs of cancer treatment for their sick children
· Providing computers, TV’s, furniture and video games for children at oncology units like the Robert Wood Johnson Bristol-Myers Squibb Children’s Hospital’s Hematology/Oncology
· Organizing Life-Saving Blood Drives
First-Line Pembrolizumab Shows A Trend Towards Overall Survival in MSI-D/dMMR mCRC
December 2nd 2023The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.
FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line
December 2nd 2023The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.
First-Line Pembrolizumab Shows A Trend Towards Overall Survival in MSI-D/dMMR mCRC
December 2nd 2023The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.
FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line
December 2nd 2023The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.
2 Clarke Drive
Cranbury, NJ 08512